Evidence map›Paper›PMID 38368443›Full record

ArticleNPJ vaccines2024

Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets.

In-Jeong Kim, Olga Gonzalez, Michael P Tighe, Paula A Lanthier, Madeline J Clark, Kelsey L Travis, Timothy C Low-Beer, Kathleen G Lanzer, Derek T Bernacki, Frank M Szaba and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Zika virus: an overview update.Current opinion in HIV and AIDS · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 1 country.

In-Jeong KimTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA. ijkim@trudeauinstitute.org.ORCID http://orcid.org/0000-0002-0408-9589
Olga GonzalezSouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Michael P TigheTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.ORCID http://orcid.org/0000-0003-3679-5688
Paula A LanthierTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.
Madeline J ClarkTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.
Kelsey L TravisTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.ORCID http://orcid.org/0000-0002-3370-4819
Timothy C Low-BeerTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.ORCID http://orcid.org/0000-0002-7372-1605
Kathleen G LanzerTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.ORCID http://orcid.org/0000-0002-3315-8547
Derek T BernackiTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.ORCID http://orcid.org/0000-0002-5934-2107
Frank M SzabaTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.
Rafael A De La BarreraPilot Bioproduction Facility, Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Vincent DussuptEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.ORCID http://orcid.org/0000-0002-8579-6356
Letzibeth Mendez-RiveraEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.
Shelly J KrebsEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.ORCID http://orcid.org/0000-0003-1136-1760
Corinna N RossSouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.ORCID http://orcid.org/0000-0003-0299-2069
Stephanie D MdakiSouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Kathleen M BraskySouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Donna Layne-ColonSouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.ORCID http://orcid.org/0000-0003-2699-2186
Suzette D TardifSouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA.
Stephen J ThomasInstitute for Global Health and Translational Sciences, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA.ORCID http://orcid.org/0000-0002-8368-7682
Kayvon ModjarradEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, 20910, USA.ORCID http://orcid.org/0000-0002-6514-5572
Marcia A BlackmanTrudeau Institute, Inc., Saranac Lake, NY, 12983, USA.ORCID http://orcid.org/0000-0002-6106-7490
Jean L PattersonSouthwest National Primate Center, Texas Biomedical Research Institute, San Antonio, TX, 78227, USA. jpatters@txbiomed.org.ORCID http://orcid.org/0000-0001-8069-8098
Trudeau Institute · USTexas Biomedical Research Institute · USHenry M. Jackson Foundation · USPfizer (United States) · USSUNY Upstate Medical University · USWalter Reed Army Institute of Research · US

Funding

The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7M
NIH HHS P51 OD011133
6 · The paper itself

Abstract

Zika virus (ZIKV) infection during pregnancy poses significant threats to maternal and fetal health, leading to intrauterine fetal demise and severe developmental malformations that constitute congenital Zika syndrome (CZS). As such, the development of a safe and effective ZIKV vaccine is a critical public health priority. However, the safety and efficacy of such a vaccine during pregnancy remain uncertain. Historically, the conduct of clinical trials in pregnant women has been challenging. Therefore, clinically relevant animal pregnancy models are in high demand for testing vaccine efficacy. We previously reported that a marmoset pregnancy model of ZIKV infection consistently demonstrated vertical transmission from mother to fetus during pregnancy. Using this marmoset model, we also showed that vertical transmission could be prevented by pre-pregnancy vaccination with Zika purified inactivated virus (ZPIV) vaccine. Here, we further examined the efficacy of ZPIV vaccination during pregnancy. Vaccination during pregnancy elicited virus neutralizing antibody responses that were comparable to those elicited by pre-pregnancy vaccination. Vaccination also reduced placental pathology, viral burden and vertical transmission of ZIKV during pregnancy, without causing adverse effects. These results provide key insights into the safety and efficacy of ZPIV vaccination during pregnancy and demonstrate positive effects of vaccination on the reduction of ZIKV infection, an important advance in preparedness for future ZIKV outbreaks.

Identifiers

PMID38368443
PMCPMC10874403
OpenAlexW4391899490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.